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QSARAbstract A series of N0-(substituted)-4-(butan-2-ylideneamino)benzohydrazides (1–21) was syn-
thesized and characterized by physicochemical as well as spectral means. The synthesized com-
pounds were screened for their in vitro antimicrobial and anticancer potentials. The synthesized
compounds displayed higher antifungal potential as compared to antibacterial potential. Besides
having good antifungal potential, the synthesized compounds were having appreciable anticancer
potential and a number of compounds displayed higher anticancer potential than the standard
drug, carboplatin. The results of QSAR studies demonstrated the importance of steric parameter,
molar refractivity (MR), topological parameters, third order molecular connectivity index (3v),
Kier’s ﬁrst order shape index (j1) in describing the antimicrobial activity of N0-(substituted)-4-
(butan-2-ylideneamino)benzohydrazides.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
One of the key objectives of organic and medicinal chemistry is
to design and synthesize molecules that possess potent thera-
peutic values. The rapid development of resistance to existing
antimicrobial drugs generates a serious challenge to the scien-
tiﬁc community. Consequently, there is a vital need for the
Synthesis, in vitro antimicrobial, anticancer evaluation and QSAR studies 449development of new antimicrobial agents with potent activity
against drug resistant microorganisms (Malhotra et al., 2011).
Cancer incidences continue to rise despite the enormous
amount of research and rapid developments during the past
decade. According to the recent statistics, cancer accounts
for about 23% of the total deaths in the USA and is the second
most common cause of death after heart disease (Hou et al.,
2011).
QSAR has been a very useful tool in designing libraries of
various ligands targeted toward particular receptors and to en-
sure increase in the probability of synthesizing therapeutically
active drugs. Therefore, to understand the inﬂuence of physio-
chemical and structural properties, QSAR studies have been
carried out (Kashaw et al., 2011).
Literature reports reveal that there are very few reports on
the biological activity of ethyl methyl ketone derivatives viz.
anticonvulsant activity (Nobuyoshi et al., 2010) and analgesic
and anti-inﬂammatory activity (Sondhi et al., 2009).
Schiff bases are considered to be among the most important
group of compounds in medicinal chemistry due to their pre-
parative accessibility, structural variety andwide biological pro-
ﬁle (Rosu et al., 2010). In continuation of our research focused
on synthesis of medicinally potent new chemical entities and
their biological screening (Judge et al., 2012a,b; Sharma et al.,
2012; Sigroha et al., 2012; Narang et al., 2012), the present study
is aimed to carry out synthesis and in vitro antimicrobial, anti-
cancer evaluation and QSAR studies of N0-(substituted)-4-(bu-
tan-2-ylideneamino)benzohydrazides.
2. Materials and methods
2.1. Instrumentation
Starting materials were obtained from commercial sources and
were used without further puriﬁcation. Reaction progress was
observed by thin layer chromatography making use of com-
mercial silica gel plates (Merck), Silica gel F254 on aluminum
sheets. Melting points were determined in open capillary tubes
on a Sonar melting point apparatus. 1H nuclear magnetic res-
onance (1H NMR) spectra were determined by a BrukerA-
vance II 400 NMR spectrometer in appropriate deuterated
solvents and are expressed in parts per million (d, ppm) down-
ﬁeld from tetramethylsilane (internal standard) NMR data are
given as multiplicity (s, singlet; d, doublet; t, triplet; m, multi-
plet) and number of protons. Infrared (IR) spectra were re-
corded on an Agilent Resolutions Pro FTIR spectrometer.
Elemental analysis was performed on a Perkin–Elmer 2400
C, H, N analyzer. Mass spectra were recorded using Waters
Micromass Q-Tof micro instrument.
2.1.1. General procedure for the synthesis of N0-(substituted)-4-
(butan-2-ylideneamino)benzohydrazides (1–21)
A solution of ethyl methyl ketone (0.01 mol) was added to the
solution of p-amino benzoic acid (0.01 mol) in ethanol and the
mixture was reﬂuxed for 3–4 h. The resulting solution was
poured on crushed ice and the precipitated solid was dried
and recrystallized from ethanol. 4-(Butan-2-ylideneamino)
benzoic acid (0.02 mol) synthesized as above was added to eth-
anol (0.5 mol) and the mixture was reﬂuxed for 1 h, in the pres-
ence of concentrated sulfuric acid (2.7 ml), cooled and poured
into ice-cold water. The solid ester separated out was ﬁltered,dried and recrystallized from ethanol (Bhat and Al-omar,
2011). 4-(Butan-2-ylideneamino) benzoate (0.01 mol) and
hydrazine hydrate 99% (0.02 mol) were reﬂuxed in 50 ml eth-
anol. The mixture was then cooled and poured into ice-cold
water. The solid product separated out was ﬁltered, dried
and recrystallized from ethanol (Bhat and Al-omar, 2011 ).
Equimolar quantities of 4-(Butan-2-ylideneamino)benzohyd-
razide (0.01 mol) and substituted aldehydes (0.01 mol) in
ethanol were reﬂuxed in the presence of a few drops of glacial
acetic acid. Then the mixture was cooled and poured into ice-
cold water. The solid product separated out was ﬁltered, dried
and recrystallized from ethanol (Ramachandran and
Maheswari, 2011).
2.2. Evaluation of antimicrobial activity
The antimicrobial activity of synthesized benzohydrazides 1-21
acid derivatives against Gram-positive bacteria: Staphylococcus
aureus, Bacillus subtilis, Gram-negative bacterium: Escherichia
coli and fungal strains: Candida albicans and Aspergillus niger
was determined using the tube dilution method (Cappucino
and Sherman, 1999). Dilutions of test and standard compounds
were prepared in double strength nutrient broth – I.P. (bacteria)
or Sabouraud dextrose broth I.P. (fungi) (Pharmacopoeia of In-
dia, 2007). The samples were incubated at 37 ± 1 C for 24 h
(bacteria), at 25 ± 1 C for 7 d (A. niger) and at 37 ± 1 C
for 48 h (C. albicans), respectively, and the results were recorded
in terms of MIC (the lowest concentration of test substance
which inhibited the growth of microorganisms).
2.3. Evaluation of anticancer activity
The anticancer activity of the synthesized compounds (1–21)
was determined against human colon (HCT116) cancer cell line.
The cell line was cultured in RPMI 1640 (Sigma) supplemented
with 10% heat inactivated fetal bovine serum (FBS) (PAA Lab-
oratories) and 1% penicillin/streptomycin (PAA Laboratories).
Cultures were maintained in a humidiﬁed incubator at 37 C in
an atmosphere of 5% CO2. Anticancer activity of the synthe-
sized compounds at various concentrations was assessed using
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
(MTT) (Sigma) assay, as described byMosmann, but with min-
ormodiﬁcation, following 72 h of incubation. Assay plates were
read using spectrophotometer at 520 nm. Data generated were
used to plot a dose–response curve from which the concentra-
tion of test compounds required to kill 50% of cell population
(IC50) was determined (Mosmann, 1983).
2.4. QSAR studies
The structures of synthesized benzohydrazide derivatives were
ﬁrst pre-optimized with the Molecular Mechanics Force Field
(MM+) procedure included in Hyperchem 6.03 (Hyperchem
6.0, 1993) and the resulting geometries are further reﬁned by
means of the semiempirical method PM3 (Parametric Meth-
od-3). We chose a gradient norm limit of 0.01 kcal/A˚ for the
geometry optimization. The lowest energy structure was used
for each molecule to calculate physicochemical properties
using TSAR 3.3 software for Windows (TSAR 3D Version
3.3, 2000). Further, the regression analysis was performed
using the SPSS software package (SPSS for Windows, 1999).
450 M. Saini et al.3. Results and discussion
3.1. Chemistry
The synthesis of target compounds, N0-(substituted)-4-(butan-
2-ylideneamino)benzohydrazides (1–21) was carried out as out-
lined in Scheme 1.All the compoundswere obtained in apprecia-
ble yield and their physicochemical characteristics are presented
in Table 1. The structures of the synthesized compounds (1–21)
were ascertained on the basis of their consistent IR, NMR and
Mass spectral characteristics in addition to elemental analysis
(C, H, N) which were in full agreement with the assigned molec-
ular structures and the data are given in Table 2.
3.2. Antimicrobial activity
The synthesized compounds were evaluated for their in vitro
antibacterial activity against S. aureus, B. subtilis, E. coli and
antifungal activity against C. albicans and A. niger by tube
dilution method using norﬂoxacin and ﬂuconazole as reference
standards for antibacterial and antifungal activity, respectively
and the results are presented in Table 3.O
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Scheme 1 Scheme for the synthesis of N0-(substituAmong the synthesized compounds, N0-(3,4-dimethoxyben-
zylidene)-4-(butan-2-ylideneamino)benzohydrazides (2) was
found to be an effective antibacterial agent against S. aureus
with pMIC values of 1.75 lM/ml. In the case of B. subtilis,
E. coli and C. albicans, N0-(4-bromobenzylidene)-4-(butan-2-
ylideneamino)benzohydrazide (6) was found to be the most
effective with pMIC values of 1.77, 1.47 and 2.07 lM/ml,
respectively (Table 3). N0-(4-hydroxybenzylidene)-4-(butan-2-
ylideneamino)benzohydrazide (12) was found to be most effec-
tive against A. niger with pMIC value of 1.76 lM/ml.
Results of antimicrobial screening indicated that the syn-
thesized compounds were found to have more potent anti-
fungal than antibacterial activity and compound 6 was found
to be the most active antifungal agent against C. albicans
(pMICca = 2.07 lM) which may be taken as lead molecule
for the development of novel antifungal agents.
3.3. Anticancer activity
The in vitro anticancer activity of the synthesized N0-(substi-
tuted)-4-(butan-2-ylideneamino)benzohydrazides against hu-
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ted)-4-(butan-2-ylideneamino) benzohydrazides.
Table 1 Physicochemical characteristics of the synthesized N0-
(substituted)-4-(butan-2-ylideneamino)benzohydrazides.
Comp. M. formula M. wt. m.p. Rf value
a % Yield
1 C19H21N3O 307 175–178 0.34 93
2 C20H23N3O3 353 144–147 0.22 82
3 C18H18ClN3O 327 101–104 0.32 83
4 C20H24N4O 336 61–64 0.27 79
5 C21H25N3O4 338 167–170 0.26 75
6 C18H18BrN3O 371 189–192 0.23 81
7 C19H21N3O2 323 117–120 0.29 87
8 C18H18ClN3O 327 112–115 0.48 84
9 C18H19N3O 293 95–98 0.34 78
10 C19H21N3O3 339 127–130 0.28 79
11 C20H23N3O3 353 177–180 0.19 80
12 C18H19N3O2 309 250–253 0.21 79
13 C18H18N4O3 338 173–176 0.15 73
14 C18H18ClN3O 327 87–90 0.06 80
15 C18H18BrN3O 372 104–107 0.21
b 90
16 C18H19N3O2 309 225–228 0.74 94
17 C20H21N3O 319 89–92 0.38 88
18 C22H21N3O2 359 235–238 0.26 81
19 C19H19N3O2 321 268–271 0.227 80
20 C16H21N3O2 287 96–99 0.41 76
21 C16H17N3O2 283 107–110 0.14 85
a Chloroform: toluene = 7:3.
b Chloroform: toluene = 1:1.
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cer potential. Compounds 1, 2, 6, 12, 13,14, 15, 19 and 20 were
found to be more potent than the standard drug carboplatin
(IC50 > 100 lM) and compound 14 (IC50 = 37.71 lM) was
found to be the most potent against human colorectal cancer
(HCT116) cell line and may be taken as new lead for the devel-
opment of novel anticancer agents. The synthesized com-
pounds however did not show good activity when compared
to the drugs available in the market which include tetrandrine,
doxorubicin and camptothecin having IC50 values of 1.530,
0.702 and 0.147 lM, respectively.
3.4. Structure activity relationship studies
The SAR for the antimicrobial and anticancer activity of N0-
(substituted)-4-(butan-2-ylideneamino)benzohydrazides can
be summarized as follows.
1. Results of the antimicrobial evaluation indicated that elec-
tron releasing groups (compounds 2 and 12 having 3,4-dime-
thoxy and p-hydroxy) on benzylidene portion improved the
antimicrobial activity of the synthesized compounds against
S. aureus and A. niger, respectively. This is in accordance
with the results obtained by Nandagokula et al. (2013).
2. Presence of electron withdrawing (p-Br) substituent on ben-
zylidene portion improved the antimicrobial activity of
compound 6 against B. subtilis, E. coli and C. albicans.
The role of electron withdrawing groups in improving anti-
bacterial and antifungal activities is supported by the stud-
ies of Mostafa et al. (2008).
3. Replacement of phenyl nucleus of benzylidene moiety with
heterocyclic (furan, 21) and alkyl groups (20) resulted in
less active antimicrobial agents, which shows that phenyl
nucleus is essential for antimicrobial activity of the synthe-
sized compounds.4. Anticancer activity results indicated that presence of o-Cl
substituent on benzylidene portion (14) improved the anti-
cancer activity of the synthesized compounds against
human colorectal cancer (HCT116) cell line.
5. From these results, we may conclude that different struc-
tural requirements are required for a compound to be effec-
tive against different targets. This is similar to the results of
Sortino et al. (2007).
The aforementioned ﬁndings are summarized in Fig. 1.
3.5. QSAR studies
In order to identify the substituent effect on the antimicrobial
activity, quantitative structure activity relationship (QSAR)
studies were undertaken, using the linear free energy relation-
ship model (LFER) described by Hansch and Fujita (1964).
In the present study, a dataset of 21 N0-(substituted)-4-(bu-
tan-2-ylideneamino)benzohydrazides (1–21) was used for
QSAR model development. Biological activity data deter-
mined as MIC values were ﬁrst transformed into pMIC values
(i.e. log MIC) and used as dependent variable in QSAR
study. The values of selected molecular descriptors used in
the QSAR study are presented in Table 5.
Our earlier studies (Sigroha et al., 2012; Judge et al.,2012a,b;
Narang et al., 2012) indicated that the multi-target QSAR (mt-
QSAR) models are better than one-target QSAR (ot-QSAR)
models in describing the antimicrobial activity. Therefore in
the present studywe developedmuti-target QSARmodels to de-
scribe the antimicrobial activity of the synthesized N0-(substi-
tuted)-4-(butan-2-ylideneamino)benzohydrazides.
According to the ot-QSARmodels one should use ﬁve differ-
ent equations with different errors to predict the activity of a new
compound against the ﬁvemicrobial species. The ot-QSARmod-
els, which are almost in the whole literature, become impractical
to use when we have to predict each compound result for more
than one target. In these cases we have to develop one ot-QSAR
for each target. However, very recently the interest has increased
in the development of multi-target QSAR (mt-QSAR) models.
As opposed to ot-QSAR, the mt-QSAR model is a single
equation that considers the nature of molecular descriptors,
which are common and essential in describing the antibacterial
and antifungal activity (Gonzalez-Diaz et al., 2008, 2007;
Cruz-Monteagudo et al., 2007; Gonzalez-Diaz and Prado-
Prado, 2008).
In the present study, we attempted to develop three differ-
ent types of mt-QSAR models viz. mt-QSAR model to describe
antibacterial activity of the synthesized compounds against S.
aureus, B. subtilis and E. coli, mt-QSAR model to describe
antifungal activity of the synthesized compounds against C.
albicans and A. niger as well as a common mt-QSAR model
to describe the antimicrobial (overall antibacterial and anti-
fungal) activity of the synthesized N0-(substituted)-4-(butan-
2-ylideneamino)benzohydrazide derivatives against all the
above mentioned microorganisms.
During the regression analysis studies it was observed that
the response values of compounds 1, 2, 3, 5, 6, 8 and 19 were
outside the limits of response values of other synthesized N0-
(substituted)-4-(butan-2-ylideneamino)benzohydrazides. Thus,
these compounds were designated as outliers and were not in-
volved in the data set for QSAR model generation. In
Table 2 Spectral studies of N0-(substituted)-4-(butan-2-ylideneamino)benzohydrazides.
Comp. IR (KBr pellets, cm1) 1H NMR (MEOD) 13C NMR (MEOD) Analytical data calcd. (found) MS ES + (ToF): m/z
[M++ 1]
1 IR (KBr pellets) cm1 3066 (C–H str., Ar), 1590
(C‚C skeletal str., phenyl), 1624 (C‚O str., sec.
amide), 1677 (C‚N str., N‚CH), 2826 (C–H
sym. str., Ar–CH3), 2955 (C–H assym. str., R–
CH3), 933 (N–N str., N–NH)
1H NMR (MEOD): 7.349–8.356
(m, 8H, Ar–H), 8.706 (s, 1H,
N‚CH), 2.503 (s, 3H, Ar–CH3),
1.219 (m, 2H, CH2 of C2H5),
0.871 (s, 3H, CH3)
23.7, 8.0, 171.9, 22.6, 152.8, 122.2,
128.5, 132.9, 128.8, 122.1, 163.3,
130.6, 129.4, 129.0, 140.5, 129.1,
129.4, 143.3, 24.2
C19H21N3O: C, 74.24; H, 6.89; N,
13.67 (C, 74.19, H, 6.91; N, 13.62)
308
2 IR (KBr pellets) cm1 3076 (C–H str., Ar), 1597
(C‚C skeletal str., phenyl), 1621 (C‚O str., sec.
amide), 1663 (C‚N str., N‚CH), 2960 (C–H
assym. str., R–CH3), 957 (N–N str., N–NH), 3120
(C–H str., OCH3), 1237 (C–O–C assym. str.,
Ar–O–CH3)
1H NMR (MEOD): 7.096–7.531
(m, 8H, Ar–H), 8.663 (s, 1H,
N‚CH), 1.241 (m, 2H, CH2 of
C2H5), 0.849 (s, 3H, CH3), 3.874
(s, 6H, OCH3)
23.5, 8.1, 171.6, 22.4, 152.5, 122.4,
128.0, 132.7, 128.4, 122.5, 163.6,
127.4, 122.8, 115.6, 152.3, 149.5,
114.7, 143.3, 56.5, 56.0
C20H23N3O3: C, 67.97; H, 6.56; N,
11.89 (C, 67.99; H, 6.52; N, 11.93)
354
3 IR (KBr pellets) cm1 3060 (C–H str., Ar), 1596
(C‚C skeletal str., phenyl), 1627 (C‚O str., sec.
amide), 1684 (C‚N str., N‚CH), 2956 (C–H
assym. str., R–CH3), 955 (N–N str., N–NH), 709
(C–Cl str., C6H5Cl)
1H NMR (MEOD): 7.340–8.018
(m, 8H, Ar–H), 8.64. (s, 1H,
N‚CH), 1.299 (m, 2H, CH2 of
C2H5), 0.896 (s, 3H, CH3)
23.2, 8.5, 171.2, 22.0, 152.7, 122.2,
128.3, 132.6, 128.1, 122.7, 163.4,
135.5, 127.7, 130.6, 131.0, 134.5,
129.4, 143.1
C18H18ClN3O: C, 65.95; H, 5.53; N,
12.82 (C, 65.91; H, 5.57; N, 12.86)
328
4 IR (KBr pellets) cm1 3070 (C–H str., Ar), 1582
(C‚C skeletal str., phenyl), 1597 (C‚O str., sec.
amide), 1654 (C‚N str., N‚CH), 2971 (C–H
assym. str., R–CH3), 938 (N–N str., N–NH), 1346
(C–N str., Aryl 3 amine)
1H NMR (MEOD): 7.438–7.617
(m, 8H, Ar–H), 8.536 (s, 1H,
N‚CH), 1.232 (m, 2H, CH2 of
C2H5), 0.874 (s, 3H, CH3), 2.532
(s, 6H, N–(CH3)2)
23.0, 8.4, 171.7, 22.3, 152.9, 122.2,
128.5, 132.6, 128.4, 122.9, 163.4,
123.7, 130.4, 114.1, 151.5, 114.8,
130.5, 143.3, 40.7, 40.1
C20H24N4O: C,71.40; H, 7.19; N,
16.65 (C,71.37; H, 7.23; N, 16.61)
337
5 IR (KBr pellets) cm1 3079 (C–H str., Ar), 1577
(C‚C skeletal str., phenyl), 1621 (C‚O str., sec.
amide), 1693 (C‚N str., N‚CH), 2953 (C–H
assym. str., R–CH3), 946 (N–N str., N–NH), 3011
(C–H str., –O–CH3), 1230 (C–O–C assym. str.,
Ar–O–CH3)
1H NMR (MEOD): 7.236–7.908
(m, 8H, Ar–H), 8.693 (s, 1H,
N‚CH), 1.277 (m, 2H, CH2 of
C2H5), 0.918 (s, 3H, CH3), 3.786
(s, 9H, OCH3)
23.5, 8.7, 171.3, 22.3, 152.6, 122.2,
128.9, 132.8, 128.4, 122.8, 163.9,
128.4, 106.9, 150.5, 141.7, 150.6,
106.5, 143.3, 56.2, 56.5, 56.0
C21H25N3O4: C, 65.78; H, 6.57; N,
10.96 (C, 65.80; H, 6.61; N, 10.92)
339
6 IR (KBr pellets) cm1 3046 (C–H str., Ar), 1582
(C‚C skeletal str., phenyl), 1624 (C‚O str., sec.
amide), 1680 (C‚N str., N‚CH), 2940 (C–H
assym. str., R–CH3), 931 (N–N str., N–NH), 595
(C–Br str., C6H5Br)
1H NMR (MEOD): 7.259–7.864
(m, 8H, Ar–H), 8.760 (s, 1H,
N‚CH), 1.232 (m, 2H, CH2 of
C2H5), 0.851 (s, 3H, CH3)
23.3, 8.5, 171.7, 22.5, 152.9, 122.5,
128.7, 132.6, 128.3, 122.5, 163.4,
132.5, 131.7, 131.9, 125.2, 131.6,
131.3, 43.4
C18H18BrN3O: C, 58.08; H, 4.87; N,
11.29 (C, 58.05; H, 4.92; N, 11.33)
372
7 IR (KBr pellets) cm1 2979 (C–H str., Ar), 1573
(C‚C skeletal str., phenyl), 1627 (C‚O str., sec.
amide), 1680 (C‚N str., N‚CH), 2937 (C–H
assym. str., R–CH3), 933 (N–N str., N–NH), 1255
(C–O–C assym. str., Ar–O–CH3)
1H NMR (DMSO): 6.553–7.987
(m, 8H, Ar–H), 8.564 (s, 1H,
N‚CH), 1.249 (m, 2H, CH2 of
C2H5), 0.873 (t, 3H, CH3), 3.843
(s, 3H, OCH3)
23.8, 8.6, 171.4, 22.0, 152.6, 122.4,
128.5, 132.2, 128.6, 122.5, 163.4,
126.5, 130.4, 114.8, 163.3, 114.1,
163.5, 114.7, 130.4, 143.2, 55.6
C19H21N3O2: C, 70.57; H, 6.55; N,
12.99 (C, 70.61; H, 6.71; N, 12.93)
324
8 IR (KBr pellets) cm1 3067 (C–H str., Ar), 1596
(C‚C skeletal str., phenyl), 1615 (C‚O str., sec.
amide), 1677 (C‚N str., N‚CH), 2957 (C–H
assym. str., R–CH3), 936 (N–N str., N–NH), 744
(C–Cl str., C6H5Cl)
1H NMR (DMSO): 7.351–8.196
(m, 8H, Ar–H), 8.888 (s, 1H,
N‚CH), 1.353 (m, 2H, CH2 of
C2H5), 0.900 (t, 3H, CH3)
23.2, 8.0, 171.1, 22.0, 152.5, 122.4,
128.5, 132.4, 128.6, 122.2, 163.0,
131.6, 130.2, 129.3, 136.8, 129.3,
130.5, 143.4
C18H18ClN3O: C, 65.95; H, 5.53; N,
12.82 (C, 65.91; H, 5.50; N, 12.85)
328
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9 IR (KBr pellets) cm1 3067 (C–H
str., Ar), 1592 (C‚C skeletal str.,
phenyl), 1623 (C‚O str., sec.
amide), 1677 (C‚N str.,
N‚CH), 2955 (C–H assym. str.,
R–CH3), 935 (N–N str., N–NH)
1H NMR (DMSO): 7.337–8.008
(m, 9H, Ar–H), 8.655 (s, 1H,
N‚CH), 1.298 (m, 2H, CH2 of
C2H5), 0.900 (t, 3H, CH3)
23.6, 8.5, 171.4, 22.4, 152.8, 122.4,
128.7, 132.4, 128.6, 122.5, 163.3,
133.5, 129.6, 128.7, 131.3, 128.5,
129.4, 143.1
C18H19N3O: C, 73.69; H, 6.53; N,
14.32 (C, 73.65; H, 6.50; N, 14.35)
294
10 IR (KBr pellets) cm1 3002 (C–H
str., Ar), 1600 (C‚C skeletal str.,
phenyl), 1624 (C‚O str., sec.
amide), 1681 (C‚N str.,
N‚CH), 2957 (C–H assym. str.,
R–CH3), 968 (N–N str., N–NH)
1238 (C–O–C assym. str., Ar–O–
CH3), 1315 (O–H in plane
bending, phenol), 1223 (C–O str.,
phenol)
1H NMR (DMSO): 6.870–7.897
(m, 7H, Ar–H), 8.324 (s, 1H,
N‚CH), 1.243 (m, 2H, CH2 of
C2H5), 0.885 (t, 3H, CH3), 3.981
(s, 3H, OCH3), 5.829 (s, 1H, OH)
23.9, 8.3, 171.1, 22.4, 152.9, 122.4,
128.7, 132.4, 128.6, 122.5, 163.3,
127.3, 116.1, 145.6, 153.9, 115.8,
122.5, 143.2, 56.5
C19H21N3O3: C, 67.24; H, 6.24; N,
12.38 (C, 67.29; H, 6.20; N, 12.40)
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11 IR (KBr pellets) cm1 3090 (C–H
str., Ar), 1581 (C‚C skeletal str.,
phenyl), 1598 (C‚O str., sec.
amide), 1629 (C‚N str.,
N‚CH), 2969 (C–H assym. str.,
R–CH3), 930 (N–N str., N–NH),
3121 (C–H str., Ar–O–CH3),
1245 (C–O–C assym. str., Ar–O–
CH3), 1345 (O–H in plane
bending, phenol), 1198 (C–O str.,
phenol)
1H NMR (DMSO): 6.878–7.700
(m, 7H, Ar–H), 8.552 (s, 1H,
N‚CH), 1.243 (m, 2H, CH2 of
C2H5), 0.905 (t, 3H, CH3), 1.365
(t, 3H, CH3 of OC2H5), 3.993 (m,
2H, CH2 of OC2H5)
23.4, 8.7, 171.6, 22.3, 152.4, 122.3,
128.5, 132.4, 128.2, 122.0, 163.3,
126.5, 115.8, 145.7, 150.2, 115.6,
122.3, 143.2, 65.0, 14.5
C20H23N3O3: C, 67.97; H, 6.56; N,
11.89 (C, 67.93; H, 6.52; N, 11.94)
354
12 IR (KBr pellets) cm1 3027 (C–H
str., Ar), 1596 (C‚C skeletal str.,
phenyl), 1622 (C‚O str., sec.
amide), 1660 (C‚N str.,
N‚CH), 2951 (C–H assym. str.,
R–CH3), 963 (N–N str., N–NH),
1303 (O–H in plane bending,
phenol), 1222 (C–O str., phenol)
1H NMR (DMSO): 6.696–7.941
(m, 8H, Ar–H), 8.394 (s, 1H,
N‚CH), 1.240 (m, 2H, CH2 of
C2H5), 0.900 (t, 3H, CH3), 5.832
(s, 1H, OH)
23.5, 8.5, 171.9, 22.3, 152.0, 122.3,
128.7, 132.4, 128.7, 122.0, 163.5,
126.7, 130.9, 116.3, 160.5, 116.1,
130.4, 143.2
C18H19N3O2: C, 69.88; H, 6.19; N,
13.58 (C, 69.83; H, 6.22; N, 13.61)
310
13 IR (KBr pellets) cm1 2958 (C–H
str., Ar), 1574 (C‚C skeletal str.,
phenyl), 1625 (C‚O str., sec.
amide), 1671 (C‚N str.,
N‚CH), 2928 (C–H assym. str.,
R–CH3), 922 (N–N str., N–NH),
842 (C–N str., Ar–NO2), 1520
(NO2 str., Ar–NO2)
1H NMR (DMSO): 7.608–8.774
(m, 8H, Ar–H), 8.851 (s, 1H,
N‚CH), 1.289 (m, 2H, CH2 of
C2H5), 0.900 (t, 3H, CH3)
23.4, 8.1, 171.6, 22.2, 152.0, 122.6,
128.7, 132.9, 128.2, 122.0, 163.9,
134.9, 135.5, 129.6, 123.2, 148.5,
124.4, 143.3
C18H18N4O3: C, 63.89; H, 5.36; N,
16.56 (C, 63.92; H, 5.40; N, 16.52)
339
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Table 2 (Continued)
Comp. IR (KBr pellets, cm1) 1H NMR (MEOD) 13C NMR (MEOD) Analytical data calcd. (found) MS ES + (ToF): m/z
[M++ 1]
14 IR (KBr pellets) cm1 3068 (C–H
str., Ar), 1588 (C‚C skeletal str.,
phenyl), 1614 (C‚O str., sec.
amide), 1678 (C‚N str.,
N‚CH), 2952 (C–H assym. str.,
R–CH3), 936 (N–N str., N–NH),
709 (C–Cl str. C6H5Cl)
1H NMR (DMSO): 7.243–7.991
(m, 8H, Ar–H), 8.886 (s, 1H,
N‚CH), 1.294 (m, 2H, CH2 of
C2H5), 0.882 (t, 3H, CH3)
23.3, 8.5, 171.3, 22.2, 152.0, 122.5,
128.7, 132.4, 128.2, 122.0, 163.3,
133.5, 130.0, 127.3, 132.7, 129.5,
134.4, 143.1
C18H18ClN3O: C, 65.95; H, 5.53; N,
12.82 (C, 65.91; H, 5.50; N, 12.87)
328
15 IR (KBr pellets) cm1 2996 (C–H
str., Ar), 1593 (C‚C skeletal str.,
phenyl), 1624 (C‚O str., sec.
amide), 1682 (C‚N str.,
N‚CH), 2959 (C–H assym. str.,
R–CH3), 940 (N–N str., N–NH),
550 (C–Br str. C6H5Br)
1H NMR (DMSO): 7.464–7.949
(m, 8H, Ar–H), 8.732 (s, 1H,
N‚CH), 1.292 (m, 2H, CH2 of
C2H5), 0.903 (t, 3H, CH3)
23.7, 8.2, 171.8, 22.5, 152.4, 122.7,
128.9, 132.7, 128.2, 122.0, 163.6,
136.4, 128.1, 131.3, 134.6, 123.5,
132.9, 143.2
C18H18BrN3O: C, 58.08; H, 4.87; N,
11.29 (C, 58.05; H, 4.83; N, 11.33)
373
16 IR (KBr pellets) cm1 2959 (C–H
str., Ar), 1598 (C‚C skeletal str.,
phenyl), 1620 (C‚O str., sec.
amide), 1678 (C‚N str.,
N‚CH), 2817 (C–H sym. str.,
R–CH3), 941 (N–N str., N–NH),
1318 (O–H in plane bending,
phenol), 1206 (C–O str., phenol)
1H NMR (DMSO): 6.737–7.716
(m, 8H, Ar–H), 8.035 (s, 1H,
N‚CH), 1.249 (m, 2H, CH2 of
C2H5), 0.898 (t, 3H, CH3), 5.436
(s, 1H, OH)
23.9, 8.0, 171.5, 22.5, 152.5, 122.3,
128.4, 132.7, 128.2, 122.3, 163.1,
118.7, 130.9, 121.3, 132.5, 116.2,
161.4, 143.1
C18H19N3O2: C, 69.88; H, 6.19; N,
13.58 (C, 69.84; H, 6.22; N, 13.60)
310
17 IR (KBr pellets) cm1 2967 (C–H
str., Ar), 1599 (C‚C skeletal str.,
phenyl), 1629 (C‚O str., sec.
amide), 1668 (C‚N str.,
N‚CH), 2923 (C–H assym. str.,
R–CH3), 974 (N–N str., N–NH),
1599 (C‚C str., CH‚CH), 1312
(C–H in plane bending
CH‚CH)
1H NMR (DMSO): 6.926–8.158
(m, 9H, Ar–H), 7.575 (d, 1H,
N‚CH), 1.282 (m, 2H, CH2 of
C2H5), 0.883 (t, 3H, CH3)
23.6, 8.2, 171.3, 22.2, 152.7, 122.4,
128.6, 132.9, 128.2, 122.3, 163.7,
137.6, 126.5, 139.3, 135.0, 126.1,
128.9, 128.3, 128.9, 126.6
C20H21N3O: C, 75.21; H, 6.63; N,
13.16 (C, 75.25; H, 6.66; N, 13.11)
320
18 IR (KBr pellets) cm1 3058 (C–H
str., Ar), 1578 (C‚C skeletal str.,
phenyl), 1621 (C‚O str., sec.
amide), 1677 (C‚N str.,
N‚CH), 2958 (C–H assym. str.,
R–CH3), 932 (N–N str., N–NH),
1306 (O–H in plane bending,
phenol), 1210 (C–O str., phenol).
1H NMR (DMSO): 7.291–7.965
(m, 10H, Ar–H), 8.051 (s, 1H,
N‚CH), 1.289 (m, 2H, CH2 of
C2H5), 0.904 (t, 3H, CH3), 5.832
(s, 1H, OH)
23.4, 8.5, 171.0, 22.5, 152.9, 122.1,
128.4, 132.6, 128.6, 122.1, 163.5,
143.3, 111.6, 161.5, 126.2, 137.4,
121.3, 126.1, 121.5, 126.8, 126.5,
127.6
C22H21N3O2: C, 73.52; H, 5.89; N,
11.69 (C, 73.47; H, 5.91; N, 11.73)
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Synthesis, in vitro antimicrobial, anticancer evaluation and QSAR studies 455multivariate statistics, it is common to deﬁne three types of
outliers (Furusjo et al., 2006).
1. X/Y relation outliers are substances for which the relation-
ship between the descriptors (X variables) and the depen-
dent variables (Y variables) is not the same as in the (rest
of the) training data.
2. X outliers are substances whose molecular descriptors do
not lie in the same range as the (rest of the) training data.
3. Y outliers are only deﬁned for training or test samples.
They are substances for which the reference value of
response is invalid.
There was no difference in the activity (Table 3) as well as
the molecular descriptor range (Table 5) of the outliers (1, 2, 3,
5, 6, 8 and 19) when compared to other N0-(substituted)-4-(bu-
tan-2-ylideneamino)benzohydrazides. This indicated the fact
that the outliers belong to the category of Y outliers (sub-
stances for which the reference value of response is invalid).
In order to develop mt-QSAR models, initially we calcu-
lated the average antibacterial activity, antifungal activity
and antimicrobial activity values of N0-(substituted)-4-(bu-
tan-2-ylideneamino)benzohydrazides which are presented in
Table 3. These average antifungal activity values correlated
with molecular descriptors of the synthesized compounds (Ta-
ble 6). In general, high colinearity (r> 0.5) was observed be-
tween different parameters (Table 6). The high
interrelationship was observed between Kier’s ﬁrst order shape
index (j1) and W (r= 0.975), and low interrelationship was
observed between energy of lowest unoccupied molecular orbi-
tal (LUMO) (r= 0.044, Table 6).
From the correlation matrix (Table 6), it was observed that
the steric parameter, molar refractivity (MR) was found to be
most effective in describing the antifungal activity of the syn-
thesized compounds (Eq. (1)).
3.5.1. LR mt-QSAR model for antifungal activity
pMICaf ¼ 0:018MR 0:078
n ¼ 14 r ¼ 0:808 q2 ¼ 0:533 s ¼ 0:088 F ¼ 22:50 ð1Þ
Here and thereafter, n – number of data points, r – correlation
coefﬁcient, q2 – cross validated r2 were obtained by leave one
out method, s – standard error of the estimate and F – Fischer
statistics.
The coefﬁcient of molar refractivity (MR) is positive in
QSAR model developed to describe the antifungal activity of
the synthesized N0-(substituted)-4-(butan-2-ylideneamino)ben-
zohydrazides (Eq. (1)), which indicated that there is a positive
correlation between antifungal activity and molar refractivity
(MR) i.e. antifungal potential of the synthesized compounds
will increase with increase in their MR values and vice versa.
This is evidenced by high antifungal activity of compound 12
(pMICaf = 1.91 lM/ml, Table 3) having high MR value
(MR= 107.38, Table 5) and minimum antifungal activity of
compound 20 (pMICaf = 1.35 lM/ml, Table 3) having least
MR value (MR= 81.63, Table 5).
The developed QSAR model (Eq. (1)) was cross validated
by q2 value (q2 = 0.533) obtained by leave one out (LOO)
method. The value of q2 (more than 0.5) indicated that the
developed model is a valid one. Further, the observed and pre-
dicted values are close to each other (Table 7), the mt-QSAR
Table 3 Antimicrobial activity (pMIC in lM/ml) of the synthesized N0-(substituted)-4-(butan-2-ylideneamino)benzohydrazides.
Comp. pMICsa pMICbs pMICec pMICca pMICan pMICab pMICaf pMICam
1 1.69 1.69 1.39 1.99 1.39 1.59 1.69 1.63
2 1.75 1.75 1.45 1.75 1.75 1.65 1.75 1.69
3 1.42 1.72 1.42 2.02 1.72 1.52 1.87 1.66
4 1.73 1.43 1.43 2.03 1.43 1.53 1.73 1.61
5 1.43 1.43 1.43 2.03 1.43 1.43 1.73 1.55
6 1.47 1.77 1.47 2.07 1.47 1.57 1.77 1.65
7 1.41 1.71 1.11 1.71 1.41 1.41 1.56 1.47
8 1.42 1.72 1.42 1.72 1.12 1.52 1.42 1.48
9 1.41 1.71 1.11 2.01 1.41 1.41 1.71 1.53
10 1.37 1.67 1.07 1.97 1.37 1.37 1.67 1.49
11 1.43 1.73 1.43 1.73 1.43 1.53 1.58 1.55
12 1.46 1.76 0.86 2.06 1.76 1.36 1.91 1.58
13 1.45 1.75 1.15 2.05 1.75 1.45 1.90 1.63
14 1.39 1.39 1.39 1.69 1.39 1.39 1.54 1.45
15 1.43 1.73 1.43 1.73 1.43 1.53 1.58 1.55
16 1.42 1.42 1.42 1.72 1.42 1.42 1.57 1.48
17 1.47 1.47 1.17 1.77 1.47 1.37 1.62 1.47
18 1.41 1.71 1.11 1.71 1.71 1.41 1.71 1.53
19 1.36 1.66 1.06 1.66 1.36 1.36 1.51 1.42
20 1.35 1.66 1.05 1.35 1.35 1.35 1.35 1.35
21 1.39 1.39 1.39 1.69 1.69 1.39 1.69 1.51
S.D. 0.12 0.14 0.19 0.19 0.17 0.09 0.15 0.09
Std. 2.61a 2.61a 2.61a 2.64b 2.64b – – –
a Norﬂoxacin.
b Fluconazole.
Table 4 Anticancer activity (IC50 in lM) of the synthesized
N0-(substituted)-4-(butan-2-ylideneamino)benzohydrazides.
Compound IC50 (HCT116, lM)
1 96.64
2 74.59
3 243.64
4 163.69
5 209.08
6 79.06
7 216.72
8 152.91
9 178.6
10 141.59
11 173.74
12 89.55
13 60.15
14 37.71
15 88.71
16 184.47
17 156.74
18 158.77
19 87.23
20 95.23
21 181.38
Tetrandrine 1.53
Doxorubicin 0.70
Camptothecin 0.15
Carboplatin >100
456 M. Saini et al.model for antibacterial activity Eq. (1) is a valid one (Gol-
braikh and Tropsha, 2002). The plot of predicted pMICaf
against observed pMICaf (Fig. 2) also favors the developed
model expressed by Eq. (1). The plot of observed pMICaf vsresidual pMICaf (Fig. 3) indicated that there was no systemic
error in model development as the propagation of error was
observed on both sides of zero (Kumar et al., 2007).
The topological parameter, third order molecular connec-
tivity index (3v) was found to be effective in describing the anti-
bacterial activity of the synthesized compounds (Eq. (2)).
3.5.2. LR mt-QSAR model for antibacterial activity
pMICab ¼ 0:2253vþ 1:117
n ¼ 14 r ¼ 0:637 q2 ¼ 0:156 s ¼ 0:051 F ¼ 8:174 ð2Þ
The molecular connectivity index, an adjacency based topolog-
ical index proposed by Randic is denoted by v and is deﬁned as
sum over all the edges (ij) as per following
v ¼
Xn
i¼1
ðViVjÞ1=2
where Vi and Vj are the degrees of adjacent vertices i and j and
n are the number of vertices in a hydrogen suppressed molec-
ular structure (Lather and Madan, 2005). The topological in-
dex, v signiﬁes the degree of branching, connectivity of
atoms and unsaturation in the molecule which accounts for
variation in activity (Gupta et al., 2003).
The addition of topological parameter, Kier’s third order
shape index (j3) to the topological parameter, third order
molecular connectivity index (3v), signiﬁcantly improved the
value of regression coefﬁcient from 0.637 to 0.778 (Eq. (3)).
3.5.3. MLR mt-QSAR model for antibacterial activity
pMICab ¼ 0:1993vþ 0:053j3 þ 0:787
n ¼ 14 r ¼ 0:778 q2 ¼ 0:296 s ¼ 0:043 F ¼ 8:46 ð3Þ
NN
H
O
N X
R
Electron 
withdrawing
groups
Electron 
releasing
groups
Increase antimicrobial activity against 
B. subtilis, E. coli and C. albicans as well 
as anticancer activity against HCT116 cell line
Increase antimicrobial activity
against S. aureus and A. niger
O
, O Less active antimicrobial agents
Figure 1 Structural requirements for antimicrobial and anticancer activities of the synthesized N0-(substituted)-4-(butan-2-
ylideneamino)benzohydrazides.
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terial activity i.e. Eq. (3) were cross validated by q2 value
(q2 = 0.296) obtained by leave one out (LOO) method. The va-
lue of q2 less than 0.5 indicated that the developed model is an
invalid one. But one should not forget the recommendations
of Golbraikh and Tropsha (2002) who reported that the only
way to estimate the true predictive power of a model is to test
their ability to predict accurately the biological activities of com-
pounds. As the observed and predicted values are close to each
other (Table 7), the mt-QSAR model for antibacterial activity
Eq. (3) is therefore a valid one (Golbraikh and Tropsha, 2002).
A set of very useful topological indices of the second gener-
ation is composed of the kappa indices of molecular shape and
ﬂexibility (Kier et al., 1999). According to Kier, the shape of a
molecule may be partitioned into attributes, each describable
by the count of bonds of various path lengths. The basis for
devising a relative index of shape is given by the relationship
of the number of path of length l in the molecule i, lPi, to some
reference values based on molecules with a given number of
atoms, n, in which the values of lP are maximum and mini-
mum, lPmax and
lPmin.
The modiﬁed kappa shape indices are given by:Table 5 Values of selected parameters used in the QSAR studies o
Comp. log P MR 2v 3v j1
1 4.95 94.28 9.56 1.39 19.33
2 3.98 102.17 10.45 1.43 22.29
3 5.00 94.04 9.58 1.39 19.33
4 4.28 102.95 10.46 1.60 21.30
5 3.73 108.63 11.18 1.57 24.27
6 5.28 96.86 9.56 1.39 19.33
7 4.23 95.70 9.73 1.30 20.31
8 5.00 94.04 9.56 1.39 19.33
9 4.89 99.48 9.65 1.10 20.31
10 4.49 89.24 8.94 1.10 18.34
11 3.95 97.40 10.26 1.50 21.30
12 5.20 107.38 11.37 1.57 21.70
13 4.29 102.15 10.67 1.52 22.29
14 4.20 90.93 9.56 1.39 19.33
15 4.44 96.56 10.47 1.60 21.30
16 5.00 94.04 9.46 1.30 19.33
17 5.28 96.86 9.58 1.39 19.33
18 4.16 95.83 9.73 1.30 20.31
19 4.16 95.83 9.73 1.30 20.31
20 3.43 81.63 8.59 1.10 17.36
21 4.20 90.93 9.46 1.30 19.33ja1 ¼ ðnþ aÞðnþ a 1Þ2=ð1Pi þ aÞ2ja2
¼ ðnþ a 1Þðnþ a 2Þ2=ð2Pi þ aÞ2ja3
¼ ðnþ a 1Þðnþ a 3Þ2=ð3Pi þ aÞ2n isoddja3
¼ ðnþ a 3Þðnþ a 2Þ2=ð3Pi þ aÞ2n is even:
The antimicrobial activity of N0-(substituted)-4-(butan-2-ylide-
neamino)benzohydrazides is best described by the topological
parameter, Kier’s ﬁrst order shape index (j1, Eq. (4)).
3.5.4. LR mt-QSAR model for antimicrobial activity
pMICam ¼ 0:0463j1 þ 0:5825
n ¼ 14 r ¼ 0:907 q2 ¼ 0:741 s ¼ 0:0309 F ¼ 55:79
ð4Þ
The validity of QSAR model for antimicrobial activity (Eq.
(4)) is indicated by their high q2 value (0.741) as well as the
low residual values (Table 7). The high residual values
observed in case outliers (1, 2, 3, 5, 6, 8 and 19) justify their
removal while developing QSAR models.
It was observed from mt-QSAR models (Eqs. (1)–(4)) that
the antibacterial activity, antifungal activity and overallf N0-(substituted)-4-(butan-2-ylideneamino)benzohydrazides.
j3 W Te LUMO HOMO
6.79 1504.00 3661.11 0.46 8.66
7.16 2092.00 4456.81 0.47 8.33
6.79 1488.00 3865.33 0.48 8.95
7.26 1924.00 4036.90 0.29 8.02
7.34 2491.00 4932.58 0.53 8.59
6.79 1504.00 3844.85 0.60 8.90
7.04 1713.00 3981.12 0.45 8.50
6.79 1504.00 3865.35 0.56 8.85
7.84 1777.00 3788.40 0.53 8.56
6.57 1318.00 3505.24 0.47 8.80
6.91 1874.00 4301.68 0.49 8.44
5.99 2194.00 4365.36 0.72 8.78
7.51 2051.00 4457.34 0.38 8.59
6.79 1504.00 3825.86 0.47 8.57
7.26 1876.00 4336.33 1.02 9.30
6.43 1472.00 3865.21 0.45 9.07
6.79 1488.00 3844.83 0.55 8.97
7.04 1713.00 3953.48 0.78 9.06
7.04 1713.00 3953.48 0.78 9.06
5.95 1151.00 3540.85 0.51 8.61
6.43 1472.00 3825.82 0.54 8.67
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Figure 2 Plot of observed pMICaf against predicted pMICaf for
the linear regression model developed by Eq. (1).
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Figure 3 Plot of observed pMICaf against residual pMICaf for
the linear regression model developed by Eq. (1).
Table 6 Correlation matrix for antifungal activity of N0-(substituted)-4-(butan-2-ylideneamino)benzohydrazides.
log P MR 3v j1 j3 J W Te LUMO pMICaf
log P 1.000
MR 0.561 1.000
3v 0.155 0.683 1.000
j1 0.227 0.893 0.794 1.000
j3 0.063 0.415 0.161 0.526 1.000
J 0.491 0.458 0.157 0.207 0.338 1.000
W 0.290 0.930 0.754 0.975 0.425 0.409 1.000
Te 0.149 0.761 0.861 0.933 0.303 0.190 0.899 1.000
LUMO 0.147 0.060 0.194 0.151 0.044 0.348 0.185 0.276 1.000
pMICaf 0.477 0.808 0.428 0.702 0.277 0.367 0.740 0.558 0.001 1.000
Table 7 Comparison of observed and predicted antimicrobial activity obtained by mt-QSAR models.
Comp. pMICab pMICaf pMICam
Obs. Pre. Res. Obs. Pre. Res. Obs. Pre. Res.
1 1.59 1.43 0.17 1.69 1.62 0.07 1.63 1.48 0.15
2 1.65 1.45 0.20 1.75 1.76 0.01 1.69 1.62 0.07
3 1.52 1.43 0.09 1.87 1.62 0.25 1.66 1.48 0.18
4 1.53 1.49 0.04 1.73 1.78 0.04 1.61 1.57 0.04
5 1.43 1.49 0.06 1.73 1.88 0.14 1.55 1.71 0.16
6 1.57 1.43 0.15 1.77 1.67 0.11 1.65 1.48 0.17
7 1.41 1.42 0.01 1.56 1.64 0.08 1.47 1.52 0.05
8 1.52 1.43 0.09 1.42 1.62 -0.20 1.48 1.48 0.00
9 1.41 1.42 0.02 1.71 1.71 0.00 1.53 1.52 0.00
10 1.37 1.36 0.01 1.67 1.53 0.14 1.49 1.43 0.06
11 1.53 1.45 0.08 1.58 1.68 -0.09 1.55 1.57 0.02
12 1.36 1.42 0.06 1.91 1.86 0.05 1.58 1.59 0.01
13 1.45 1.49 0.04 1.90 1.76 0.14 1.63 1.62 0.01
14 1.39 1.43 0.03 1.54 1.56 0.02 1.45 1.48 0.03
15 1.53 1.49 0.04 1.58 1.66 0.08 1.55 1.57 0.02
16 1.42 1.39 0.03 1.57 1.62 0.05 1.48 1.48 0.00
17 1.37 1.43 0.05 1.62 1.67 0.04 1.47 1.48 0.01
18 1.41 1.42 0.01 1.71 1.65 0.06 1.53 1.52 0.01
19 1.36 1.42 0.06 1.51 1.65 0.14 1.42 1.52 0.10
20 1.35 1.32 0.03 1.35 1.39 0.04 1.35 1.39 0.03
21 1.39 1.39 0.00 1.69 1.56 0.14 1.51 1.48 0.03
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(butan-2-ylideneamino)benzohydrazides are governed by the
steric parameter, molar refractivity (MR) and topological
parameters, Kier’s ﬁrst order shape index (j1) third order
molecular connectivity index (3v).
Generally for QSAR studies, the biological activities of
compounds should span 2–3 orders of magnitude. But in the
present study the range of antimicrobial activities of the syn-
thesized compounds is within one order of magnitude. This
is in accordance with results suggested by Bajaj et al. (2005)
who stated that the reliability of the QSAR model lies in its
predictive ability even though the activity data are in the nar-
row range. When biological activity data lie in the narrow
range, the presence of minimum standard deviation of the bio-
logical activity justiﬁes its use in QSAR studies (Narasimhan
et al., 2007). The minimum standard deviation (Table 3) ob-
served in the antimicrobial activity data justiﬁes its use in
QSAR studies.4. Conclusion
In the present study, a series of N0-(substituted)-4-(butan-2-
ylideneamino)benzohydrazides (1–21) was synthesized
(Scheme 1) and screened for its in vitro antimicrobial and anti-
cancer potentials. The results of antimicrobial studies indi-
cated the synthesized compounds were more potent toward
C. albicans than other microbial strains tested and compound
6 was found to be the most active antifungal agent (pMIC-
ca = 2.07 lM/ml). Anticancer activity revealed that compound
14 (IC50 = 37.71 lM) was found to be the most potent. The
results of QSAR studies demonstrated the importance of steric
parameter, molar refractivity (MR), topological parameters,
third order molecular connectivity index (3v), Kier’s ﬁrst order
shape index (j1) in describing the antimicrobial activity of N0-
(substituted)-4-(butan-2-ylideneamino)benzohydrazides.References
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